Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Nicotinamide Riboside: Nicotinamide Riboside has the stronger overall evidence (5.5 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Nicotinamide Riboside wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (canagliflozin)
1000 mg daily (the dose used in most outcome trials; lower doses raise blood NAD+ but have not been tested for clinical effects)
Morning with breakfast, Split dosing (morning and midday) for doses above 500 mg
Nicotinamide Riboside Chloride capsules or powder
and 1 more not shown
Weeks
Unknown in humans
Months to years
Weeks to months
1–2 weeks
4–8 weeks
8–16 weeks
4–8 weeks
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Ageing Research Reviews (2026) · Systematic review
Reviewed 113 intervention studies published from 2010 to October 2025: 33 in humans (28 of them randomised) and 80 in rodents, covering NR, NMN and injected NAD+.
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Journal of Cachexia, Sarcopenia and Muscle (2025) · Meta analysis
Systematic review and meta-analysis of placebo-controlled RCTs of NMN or NR in adults with a mean age of 60.9 to 83 years, looking at muscle mass, grip strength, gait speed and other physical performance tests.
Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis.
Nutrition & Metabolism (2022) · Meta analysis · n=14750
Meta-analysis of 40 clinical studies (14,750 participants) of four NAD+ precursors: nicotinamide riboside, nicotinamide mononucleotide, nicotinic acid (niacin) and nicotinamide.
The points come from one 8-week RCT in overweight adults, where 100, 300 and 1,000 mg a day raised whole-blood NAD+ by 22%, 51% and 142%, with no difference in adverse events versus placebo or between doses (PMID 31278280). Other trials at 1 g a day found similar rises, 2.6-fold in older adults with mild cognitive impairment (PMID 37994989). No trial compared doses above 1,000 mg, so no optimal dose is plotted. The ceiling is the 2,000 mg a day that a 12-week RCT in obese men found safe (PMID 29992272). The NR-SAFE trial also found 3,000 mg a day well tolerated over 4 weeks in 10 people with Parkinson's disease (PMID 38016950).
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide Riboside has a higher evidence score (5.5/10 vs 4.5/10) and wins in 2 of 3 categories.
For support heart health, Canagliflozin has a higher relevance score (70 vs 62).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.